Beta

Talphera, inc.TLPH.US Overview

US StockHealthcare
(No presentation for TLPH)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

TLPH AI Insights

TLPH Overall Performance

TLPH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TLPH Recent Performance

3.52%

Talphera, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

TLPH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check TLPH's Trend

TLPH Key Information

TLPH Valuation Metrics

TLPH Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.

Price of TLPH

TLPH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TLPH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.70
PE Ratio (TTM)
-
Forward PE
1.02
PS Ratio (TTM)
1385.31
PB Ratio
2.31
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-51035.71%
Revenue Growth (YoY)
-90.04%
Profit Growth (YoY)
-90.04%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.70
PE Ratio (TTM)
-
Forward PE
1.02
PS Ratio (TTM)
1385.31
PB Ratio
2.31
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-51035.71%
Revenue Growth (YoY)
-90.04%
Profit Growth (YoY)
-90.04%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is TLPH's latest earnings report released?

    The most recent financial report for Talphera, inc. (TLPH) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TLPH's short-term business performance and financial health. For the latest updates on TLPH's earnings releases, visit this page regularly.

  • How much cash does TLPH have?

    At the end of the period, Talphera, inc. (TLPH) held Total Cash and Cash Equivalents of 5.89M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TLPH's EPS continuing to grow?

    According to the past four quarterly reports, Talphera, inc. (TLPH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TLPH?

    Talphera, inc. (TLPH)'s Free Cash Flow (FCF) for the period is -2.44M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 8.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TLPH?

    The latest valuation data shows Talphera, inc. (TLPH) has a Price-To-Earnings (PE) ratio of -2.81 and a Price/Earnings-To-Growth (PEG) ratio of 0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.